To the best of our knowledge, this is the first reported case of successful dose re-escalation overcoming amplification-mediated resistance in KRAS G12C-mutant NSCLC following disease progression after dose reduction due to toxicity, offering valuable insights on this emerging patients’ population as KRAS G12C inhibitors are expected to become a standard treatment for a large number of NSCLC patients in the next future. Here, KRAS is linked to non-small cell lung carcinoma.